Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Genome Medicine
|
December 17, 2015
A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation
Dirk S Paul, Allison Jones, Rob S Sellar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial
Nigel H Russell, Abin Thomas, Robert K Hills, et al.
British Journal of Haematology
|
August 10, 2019
Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia
Rob S Sellar, Varun Mehra, Thomas A Fox, et al.
Blood
|
August 18, 2023
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Sylvie D Freeman, Abin Thomas, Ian Thomas, et al.
Blood Cancer Discovery
|
May 24, 2021
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies
Aline Renneville, Jessica A Gasser, Daniel E Grinshpun, et al.
Blood
|
May 3, 2019
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
Adam S Sperling, Michael Burgess, Hasmik Keshishian, et al.
Nature
|
June 5, 2020
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Mikołaj Słabicki, Zuzanna Kozicka, Georg Petzold, et al.
Science Translational Medicine
|
April 13, 2018
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
Ofir Wolach, Rob S Sellar, Kimberly Martinod, et al.
Blood
|
November 14, 2025
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18
Steven Knapper, Laura W Dillon, Malavika Babu, et al.
The Journal of Clinical Investigation
|
June 28, 2022
Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells
Rob S Sellar, Adam S Sperling, Mikołaj Słabicki, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Genome Medicine
|
December 17, 2015
A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation
Dirk S Paul, Allison Jones, Rob S Sellar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial
Nigel H Russell, Abin Thomas, Robert K Hills, et al.
British Journal of Haematology
|
August 10, 2019
Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia
Rob S Sellar, Varun Mehra, Thomas A Fox, et al.
Blood
|
August 18, 2023
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Sylvie D Freeman, Abin Thomas, Ian Thomas, et al.
Blood Cancer Discovery
|
May 24, 2021
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies
Aline Renneville, Jessica A Gasser, Daniel E Grinshpun, et al.
Blood
|
May 3, 2019
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
Adam S Sperling, Michael Burgess, Hasmik Keshishian, et al.
Nature
|
June 5, 2020
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Mikołaj Słabicki, Zuzanna Kozicka, Georg Petzold, et al.
Science Translational Medicine
|
April 13, 2018
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
Ofir Wolach, Rob S Sellar, Kimberly Martinod, et al.
Blood
|
November 14, 2025
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18
Steven Knapper, Laura W Dillon, Malavika Babu, et al.
The Journal of Clinical Investigation
|
June 28, 2022
Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells
Rob S Sellar, Adam S Sperling, Mikołaj Słabicki, et al.
Page
of 4